Skip to main content
Premium Trial:

Request an Annual Quote

Courtagen Inks Emerging Markets Deal with Alliance Global Group

NEW YORK (GenomeWeb News) – Courtagen Life Sciences today said that Alliance Global Group will distribute the firm's molecular diagnostic tests in certain emerging markets.

Dubai-based Alliance Global sells biomedical products in the Middle East, Africa, and Asia. It will have exclusive rights to distribute a number of Courtagen tests for genetically based disorders. Thus far, the Woburn, Mass.-based firm offers tests for mitochondrial disorders and a new panel for epilepsy and seizure. Courtagen also plans to develop tests for other neurological disorders.

Financial and other terms of the agreement were not disclosed.

Courtagen runs a CLIA lab that develops sequencing-based tests and uses the firm's proprietary bioinformatics platform called ZiPhyr.

Brian McKernan, CEO of Courtagen, said in a statement that the pact with Alliance Global "is a critical component of Courtagen's international business expansion."

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.